NFE2L3
Basic information
Region (hg38): 7:26152198-26187137
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the NFE2L3 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 1 | |||||
missense | 56 | 60 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 0 | 56 | 4 | 1 |
Variants in NFE2L3
This is a list of pathogenic ClinVar variants found in the NFE2L3 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
7-26152575-TC-T | Neurodevelopmental disorder | Uncertain significance (Jun 19, 2024) | ||
7-26152580-G-A | not specified | Uncertain significance (Mar 19, 2024) | ||
7-26152630-C-A | not specified | Uncertain significance (Jan 23, 2023) | ||
7-26152649-G-T | not specified | Uncertain significance (May 25, 2022) | ||
7-26152668-A-G | not specified | Uncertain significance (Oct 05, 2021) | ||
7-26152710-C-T | not specified | Uncertain significance (Sep 13, 2023) | ||
7-26152715-C-T | not specified | Uncertain significance (Aug 17, 2021) | ||
7-26152733-C-G | not specified | Uncertain significance (Jun 22, 2024) | ||
7-26152781-G-T | not specified | Uncertain significance (Jan 29, 2024) | ||
7-26152794-G-A | not specified | Uncertain significance (May 18, 2023) | ||
7-26152835-G-C | not specified | Uncertain significance (Nov 22, 2022) | ||
7-26152844-G-A | not specified | Uncertain significance (Aug 26, 2022) | ||
7-26152847-G-A | not specified | Uncertain significance (Jun 21, 2021) | ||
7-26152893-C-T | not specified | Uncertain significance (May 30, 2024) | ||
7-26152931-G-T | Neurodevelopmental disorder | Uncertain significance (Jun 19, 2024) | ||
7-26152974-C-A | not specified | Uncertain significance (Dec 21, 2022) | ||
7-26152974-C-T | not specified | Uncertain significance (Jan 23, 2024) | ||
7-26153037-A-C | not specified | Uncertain significance (Jul 26, 2022) | ||
7-26153048-G-A | not specified | Uncertain significance (Jul 12, 2022) | ||
7-26177970-G-A | not specified | Uncertain significance (Apr 10, 2023) | ||
7-26177976-G-T | not specified | Uncertain significance (Oct 25, 2022) | ||
7-26178021-G-C | not specified | Uncertain significance (Sep 01, 2021) | ||
7-26178073-C-T | not specified | Uncertain significance (Nov 09, 2023) | ||
7-26183702-G-C | not specified | Uncertain significance (Dec 21, 2022) | ||
7-26183723-C-T | not specified | Uncertain significance (Mar 29, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
NFE2L3 | protein_coding | protein_coding | ENST00000056233 | 4 | 34886 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
7.18e-11 | 0.136 | 125471 | 1 | 276 | 125748 | 0.00110 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -3.75 | 512 | 323 | 1.59 | 0.0000157 | 4508 |
Missense in Polyphen | 102 | 62.167 | 1.6407 | 909 | ||
Synonymous | -4.64 | 195 | 128 | 1.52 | 0.00000640 | 1380 |
Loss of Function | 0.504 | 17 | 19.4 | 0.876 | 9.23e-7 | 270 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00223 | 0.00223 |
Ashkenazi Jewish | 0.000397 | 0.000397 |
East Asian | 0.00316 | 0.00316 |
Finnish | 0.0000925 | 0.0000924 |
European (Non-Finnish) | 0.000759 | 0.000756 |
Middle Eastern | 0.00316 | 0.00316 |
South Asian | 0.00213 | 0.00209 |
Other | 0.00212 | 0.00212 |
dbNSFP
Source:
- Function
- FUNCTION: Activates erythroid-specific, globin gene expression.;
Recessive Scores
- pRec
- 0.0952
Intolerance Scores
- loftool
- 0.630
- rvis_EVS
- 0.2
- rvis_percentile_EVS
- 67.43
Haploinsufficiency Scores
- pHI
- 0.506
- hipred
- N
- hipred_score
- 0.153
- ghis
- 0.452
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.534
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Nfe2l3
- Phenotype
- normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span);
Gene ontology
- Biological process
- negative regulation of transcription by RNA polymerase II;transcription by RNA polymerase II;positive regulation of transcription, DNA-templated
- Cellular component
- nucleus;cytoplasm
- Molecular function
- transcription regulatory region sequence-specific DNA binding;RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription repressor activity, RNA polymerase II-specific;DNA-binding transcription factor activity;transcription coactivator activity;protein binding